Transcript
SCIENCE AND TECHNOLOGY
BY
DHIVYA JAYARAMAN
FINANCE
+25%$.1+10%$.320. Biocon (India)
NA($.1)+25%$.319. Nektar Therapeutics (U.S.)
100%($.1)+55%$.318. Crucell (Netherlands)
>999%$.1+51%$.317. Cubist Pharmaceuticals (U.S.)
NA(>$.1)+84%$.316. Abraxis Bioscience (U.S.)
>999%$.1+41%$.315. OSI Pharmaceuticals (U.S.)
NA>$.1+9%$.514. Millenium Pharmaceuticals (U.S.)
(>999%)>$.1(13%)$.613. ImClone Systems (U.S.)
(65%)($.4)+36%$.812. Elan (Ireland)
+3%($.2)+53%$.811. Amylin Pharmaceuticals (U.S.)
(49%)$.1+39%$1.110.Actelion (Switzerland)
+128%$.2+56%$1.49. Celgene (U.S.)
(>999%)($.2)+1%$1.88. Cephalon (U.S.)
+359%$.5+14%$2.87. CSL ( Australia)
+193%$.6+18%$3.26. Biogen Idec (U.S.)
>999%$.5+20%$3.85. Genzyme (U.S.)
>999%$1.6+40%$4.24. Gilead Sciences (U.S.)
(56%)$.2+42%$5.03. UCB (Belgium)
+31%$2.8+26%$11.72. Genentech (U.S.)
+7%$3.2+4%$14.81. Amgen (U.S.)
% Growth2007 Income
(billions)
% Growth2007 Revenue
(billions)
Company/Country
93.840.3354028Net Profit
48.2----Exceptional Item, Net
45.440.3354028Profit From Operations
1317311823Income Tax
4843.841.343.632.7Profit Before Tax
172156118.6104.676.6Total
1913.55.84.43.2Depreciation
21.80.40.40.4Interest and Finance Charges
151140.6112.498.473Manufacturing & Other Expenses
Expenditure
220200160147110Total Revenues
7.20.8130.2Other Income
212.6198.8159143.3109.8Total
44.432.82013.37.8Contract Research and Technical Licensing Fees
9.219171814Enzymes
15914712211288Bio Pharmaceuticals
Sales
20082007200620052004 In Thousand USD ($ 1000)
MARKETING BY XIAOYU LIANG
Until 2007 Global about 140millions
Strength Weakness
Opportunity Threat
top related